Back to search results

Obstructive Sleep Apnea and Normal Tension Glaucoma Study

This research study is looking into the connection between Obstructive Sleep Apnea (OSA), a condition where breathing stops and starts during sleep, and Normal Tension Glaucoma (NTG). NTG is a type of glaucoma that damages the optic nerve and can lead to vision loss, even when eye pressure is normal. Researchers want to see if treating OSA with CPAP (Continuous Positive Airway Pressure) therapy might help improve blood flow to the eye and reduce early signs of vision problems in people with NTG. You might be able to join if you are at least 21 years old, have newly diagnosed OSA, and are starting CPAP treatment. The study will observe participants over 9 months to see if there are changes in glaucoma diagnostic parameters. The study is currently unclear on its recruitment status and plans to enroll 100 participants.

Study design
This is an observational study, meaning researchers will observe participants without providing specific treatments beyond their usual care. It aims to enroll 100 participants.
What's involved
You would have a glaucoma evaluation at the start and three follow-up visits over a 9-month period, including structural and functional diagnostic tests.
Compensation
Not stated in the trial record.
Follow-up
The study will measure primary outcomes related to glaucoma over a period of 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06023927

Obstructive Sleep Apnea as a Risk Factor for Normal Tension Glaucoma and a Crucial Step in Preventing Blindness

Not Yet Recruiting
Not specifiedAges 21+Observational
Northwell Health
~100 participants
Updated 2025-06-10 on ClinicalTrials.gov
What's tested:Clinical observation, diagnostic testing

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prevalence of NTG
Measured over 2 years
+3 more outcomes measured

Conditions

Normal Tension Glaucoma
Obstructive Sleep Apnea

Explore related trials

Low tension glaucomaObstructive Sleep Apnea

Where it's being run

2 sites across 1 states
New York2

Who to contact

Andrew Tirsi, MD
[email protected]
201-982-4168
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Newly diagnosed subjects with OSA that will undergo CPAP treatment.
At least 21 years of age
Best corrected vision of 20/40 or better, spherical Rx \< ± 6.0 Diopter, and cylinder \<-3.0D
Ability to follow instructions, and intent to complete all study visits

Exclusion

High Rx \>± 6.0D and cylinder \> -3.0D
Narrow angle glaucoma
History of any of the following: severe eye trauma, ocular inflammation, previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation.
Any medical or ocular condition which is not appropriate for participation in the trial (Diabetic retinopathy, and other retinal changes preventing reliable optic disc evaluation) Hypersensitivity to any component of altafluor benox

What this trial measures

  • Prevalence of NTG2 years

    To determine the prevalence of normal tension glaucoma (NTG) in newly-diagnosed subjects with different stages of obstructive sleep apnea (mild, moderate, and severe)

  • Mean difference in diagnostic parameters at baseline2 years

    Mean difference in pattern electroretinogram (PERG) parameters (in millivolts) and optical coherence tomography angiography (OCTA) Vessel density (VD) measurements at baseline between the 3 OSA study groups (mild, moderate, and severe).Magnitude (mV), MagnitudeD (MagD) (mV), MagD/Mag ratio and VD (%) will be compared across 3 OSA groups

  • Mean change in diagnostic parameters at follow up intervals2 years

    Mean change in PERG parameters (in millivolt) and OCTA vessel density measurements (%) in each of the follow up visits compared to baseline

  • Two PERG devices will be compared in their ability to detect retinal ganglion cell dysfunction2 years

    Diopsys NOVA PERG parameters will be correlated with PERG SmartEP parameters (in millivolts)